Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China

First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN)  Approval based on positive interim Phase 3 TELIGAN results generated by collaborator RemeGen and recently published in The New England Journal of Medicine IgAN marks the fourth indication approval for telitacicept BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, and RemeGen Co., Ltd., (HKEX: 9995, SHA: 688331) today announced that China's National Medicinal Products Administration (NMPA) has conditionally approved telitacicept for the treatment of adult patients with IgAN.

GlobeNewsWire • Jun 8, 2026

Telitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in China

First regulatory approval for Sjögren's disease (SjD) First and only approved therapy for SjD in China Approval based on positive Phase 3 results generated by collaborator RemeGen demonstrating statistically significant and clinically meaningful improvements in both ESSDAI and ESSPRI SjD marks the fifth indication approval for telitacicept BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, and RemeGen Co., Ltd., (HKEX: 9995, SHA: 688331) today announced that China's National Medicinal Products Administration (NMPA) has approved telitacicept for the treatment of adult patients with SjD.

GlobeNewsWire • Jun 8, 2026

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on June 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 61,050 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 12,900 shares of Vor Bio's common stock to 10 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).

GlobeNewsWire • Jun 1, 2026

Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference

BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will provide a corporate update in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY.

GlobeNewsWire • May 28, 2026

Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine

Interim analysis demonstrated a 55.0% relative reduction in proteinuria versus placebo at 39 weeks with eGFR remaining stable through treatment  Results further support the potential for telitacicept to become a best-in-class dual BAFF/APRIL therapy across autoimmune diseases BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that results from the Phase 3 TELIGAN trial evaluating telitacicept in IgA nephropathy in China sponsored by its collaborator, RemeGen Co., Ltd., (HKEX: 9995, SHA: 688331), were published in The New England Journal of Medicine (NEJM).

GlobeNewsWire • May 14, 2026

Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of telitacicept in primary Sjögren's disease Cash and investment balance of $491.5 million as of March 31, 2026 expected to provide runway into early 2029 BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. “We had another quarter of solid execution for our two global Phase 3 programs in generalized myasthenia gravis and primary Sjögren's disease, both of which are progressing as planned,” said Jean-Paul Kress, M.D.

GlobeNewsWire • May 13, 2026

Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade

The consensus price target hints at a 124.6% upside potential for Vor Biopharma (VOR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • May 7, 2026

Does Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 117% in Vor Biopharma (VOR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research • Apr 20, 2026

Vor Biopharma: It's A Game Of Wait And See

Vor Biopharma Inc. has pivoted to immunology, raising over $500m in 2025 to advance telitacicept for U.S. approval. VOR holds $530m cash, extending its runway into 2029, but faces significant dilution risk from outstanding warrants and equity plans. Telitacicept, already approved in China for multiple indications, must now clear pivotal Phase 3 US trials, with data not expected until 2027.

Seeking Alpha • Apr 8, 2026

Wall Street Analysts Predict a 107.82% Upside in Vor Biopharma (VOR): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 107.8% in Vor Biopharma (VOR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research • Apr 2, 2026